/PRNewswire/ The allergy immunotherapies market is expected to grow by USD 1.01 billion from 2022 to 2027. In addition, the momentum of the market will.
To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.